MARKET

NSPR

NSPR

INSPIREMD
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.340
+0.010
+0.23%
After Hours: 4.330 -0.01 -0.23% 16:16 09/24 EDT
OPEN
4.250
PREV CLOSE
4.330
HIGH
4.360
LOW
4.225
VOLUME
73.52K
TURNOVER
--
52 WEEK HIGH
22.20
52 WEEK LOW
3.600
MARKET CAP
34.35M
P/E (TTM)
-0.3994
1D
5D
1M
3M
1Y
5Y
Increasing Incidences of Cardiac Arrhythmias Raising Demand for Electrophysiology Medical Devices - Financial News Media
Palm Beach, FL - September 21, 2021 – FinancialNewsMedia.com News Commentary Growing prevalence of cardiovascular disorders (CVDs) globally is anticipated to substantially increase in the upcoming years. Hypertension, smoking, alcohol consumption, and cons...
MENAFN · 4d ago
BioSig Technologies, Inc. Appoints Medical Device Industry Leader to its Board of Directors
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, tod...
GlobeNewswire · 4d ago
InspireMD Granted Canadian Patent Titled 'INTRAVASCULAR ANEURYSM TREATMENT DEVICE AND METHODS'
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3013758/summary.html
Benzinga · 09/15 17:10
60 Biggest Movers From Yesterday
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.
Benzinga · 08/30 09:18
NeuroMetrix, Reneo Pharmaceuticals leads healthcare gainers; Cassava Sciences, Applied Therapeutics among major losers
Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Therape...
Seekingalpha · 08/27 15:06
InspireMD Reports Narrower Loss In Q2 As Revenue Rebounds On Procedural Recovery
Benzinga · 08/10 21:34
FCEL, MVST and ASTR among pre market gainers
Lightning eMotors ZEV +44% on signing largest contract ever in the electric shuttle bus market with Forest River Fulcrum Therapeutics FULC +53% on early-stage results for sickle cell disease therapy IMV IMV +39% on promising maveropepimut-S
Seekingalpha · 08/10 12:55
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 08/10 12:07
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NSPR. Analyze the recent business situations of INSPIREMD through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NSPR stock price target is 16.50 with a high estimate of 16.50 and a low estimate of 16.50.
EPS
Institutional Holdings
Institutions: 20
Institutional Holdings: 479.29K
% Owned: 6.06%
Shares Outstanding: 7.91M
TypeInstitutionsShares
Increased
5
98.94K
New
4
54.73K
Decreased
4
148.02K
Sold Out
8
22.28K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Chairman/Director
Paul Stuka
Chief Executive Officer/Director
Marvin Slosman
Vice Chairman/Director
Isaac Blech
Chief Financial Officer/Chief Administrative Officer/Treasurer/Secretary/IR Contact Officer
Craig Shore
Executive Vice President
Agustin Gago
Director
Kathryn Arnold
Director
Thomas Kester
Director
Gary Roubin
Independent Director
Michael Berman
Independent Director
Campbell Rogers
No Data
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Webull offers kinds of InspireMD Inc stock information, including NASDAQ:NSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NSPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NSPR stock methods without spending real money on the virtual paper trading platform.